Mark Johnson Consultant Urological Surgeon Newcastle

Mark Johnson Consultant Urological Surgeon Newcastle – Expert in Urology Care

Mark Johnson Consultant Urological Surgeon Newcastle provides world-class urological care at the Freeman Hospital. As a leading figure in the field, Mr Johnson brings over two decades of hands-on surgical experience to the region. With every patient, he applies his expertise in robotic-assisted techniques to ensure the best possible outcomes.

Professional Background and Education

Mark Johnson began his medical career with a brief stint in histopathology. However, he soon transitioned into basic surgical training in Leeds. After that, he pursued groundbreaking research into prostate cancer at Newcastle University. This period of study sharpened his knowledge of the disease’s molecular biology and laid a strong foundation for his future in urology.

Surgical Training and Career Milestones

Following his research, Mr Johnson completed higher surgical training in the Northern region. This advanced training prepared him for the challenges of complex urological procedures. As a result, he became a Consultant Urological Surgeon in 2004. Since then, he has led many successful surgeries and contributed to innovations in his field.

Focus on Robotic-Assisted Cancer Surgery

Mark Johnson Consultant Urological Surgeon Newcastle has a clear focus on robotic-assisted surgeries. These cutting-edge procedures play a vital role in the treatment of prostate and bladder cancers. Because of his specialization, many patients across the North East seek his expertise. He continuously updates his skills and techniques to stay at the forefront of minimally invasive surgery.

Leadership in National and Regional Cancer Networks

In addition to clinical work, Mr Johnson actively contributes to national and regional cancer organizations. He is a valued member of the National Cancer Research Institute’s Bladder Cancer Studies Group. Furthermore, he has chaired the North of England Cancer Network Urology Tumour Specific Group. Through these roles, he helps shape the future of urological cancer treatment across the UK.